nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2015 | Review – Cancer Research

Oncogenes associated with drug resistance in ovarian cancer

verfasst von: Xia Liu, Yutao Gao, Yi Lu, Jian Zhang, Li Li, Fuqiang Yin

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Oncogenes play pivotal roles in the development of cancer, and disturbances in their expression have been implicated in drug resistance. However, an overview of the contribution of oncogenes to drug resistance in ovarian cancer has not previously been reported. This study aimed to review the drug resistance-related oncogenes in ovarian cancer and precisely determine their relationships.

Methods

The oncogenes associated with drug resistance in ovarian cancer from available papers were summarized, and a comprehensive bioinformatics analysis including pathway enrichment, biological processes annotation, protein/gene interaction and microRNA–mRNA interaction was performed.

Results

Total of 25 oncogenes contributing to drug resistance in ovarian cancer was integrated and further analyzed. An oncogene-mediated drug resistance pathway that explains the associations of 21 of these oncogenes in drug resistance was drafted on the basis of previously published papers. The downstream location of v-akt murine thymoma viral oncogene (AKT) and B-cell CLL/lymphoma 2-associated X protein (BAX) with respect to many other oncogenes was determined, indicating that the two genes may play a central role, and the AKT- and BAX-mediated signaling are the main pathways accounting for the involvement of oncogenes in drug resistance in ovarian cancer. Besides, the annotation of biological process indicated that the apoptosis (cell death) and phosphorylation (phosphate metabolic process) might be the two major biological routes through which oncogenes contribute to drug resistance in ovarian cancer. In addition, on the basis of the comprehensive analysis of microRNA–mRNA interactions, 11 microRNAs were identified to be targeted at least 7 of the 25 oncogenes, indicating that those microRNAs could be an important regulator of the 25 oncogenes. Collectively, by integrating and further analyzing the available data on these oncogenes, this study contributes to improving our understanding of the mechanisms by which their expression leads to drug resistance in this ovarian cancer.

Abe A, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K, Satoh T, Oki A, Yoshikawa H (2013) PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum Pathol 44:199–207PubMed

Acosta KB, Tibolla MM, Tiscornia MM, Lorenzati MA, Zapata PD (2011) Recent patents related to phosphorylation signaling pathway on cancer. Recent Pat DNA Gene Seq 5:175–184PubMed

Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC (2010) Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 116:3276–3284PubMedCentralPubMed

Auner V, Kriegshauser G, Tong D, Horvat R, Reinthaller A, Mustea A, Zeillinger R (2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9:111PubMedCentralPubMed

Aunoble B, Sanches R, Didier E, Bignon YJ (2000) Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 16:567–576PubMed

Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428PubMedCentralPubMed

Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280–285PubMed

Berchuck A, Kohler MF, Bast RC Jr (1992) Oncogenes in ovarian cancer. Hematol Oncol Clin N Am 6:813–827

Brazil DP, Park J, Hemmings BA (2002) PKB binding proteins. Getting in on the Akt. Cell 111:293–303PubMed

Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529PubMed

Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D (2008) Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29:1893–1900PubMedCentralPubMed

Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V (2013) miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 32:341–351PubMed

Chan JK, Pham H, You XJ, Cloven NG, Burger RA, Rose GS, Van Nostrand K, Korc M, Disaia PJ, Fan H (2005) Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res 65:3243–3248PubMed

Chen T, Pengetnze Y, Taylor CC (2005) Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 4:217–224PubMed

Chen AP, Zhang J, Liu H, Zhao SP, Dai SZ, Sun XL (2009a) Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma. Zhonghua Zhong Liu Za Zhi 31:48–52PubMed

Chen H, Sun JG, Cao XW, Ma XG, Xu JP, Luo FK, Chen ZT (2009b) Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559. Biochem Biophys Res Commun 385:596–600PubMed

Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, Shih Ie M (2009) Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res 69:1407–1415PubMedCentralPubMed

Codegoni AM, Bertoni F, Colella G, Caspani G, Grassi L, D’Incalci M, Broggini M (1999) Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer. Oncol Res 11:297–301PubMed

Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502–511PubMed

Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122:6–7PubMed

da Huang W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1–13PubMedCentral

Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ (2004) Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23:706–715PubMed

Davidson B, Trope CG, Wang TL, Shih Ie M (2006) Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol 103:814–819PubMed

del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687–689PubMed

Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D’Incalci M, De Placido S, Pepe S (2012) A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 83:1113–1119PubMed

Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B, Hondermarck H, Peyrat JP (2001a) Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 61:4337–4340PubMed

Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP, Hondermarck H (2001b) Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 276:17864–17870PubMed

Diehl KM, Keller ET, Ignatoski KMW (2007) Why should we still care about oncogenes? Mol Cancer Ther 6:418–427PubMed

Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB (2006) A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci USA 103:15014–15019PubMedCentralPubMed

Dobrzycka B, Terlikowski SJ, Kinalski M, Kowalczuk O, Niklinska W, Chyczewski L (2011) Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Ann Oncol 22:1133–1140PubMed

Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk—database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 44:839–847PubMed

Ecker A, Simma O, Hoelbl A, Kenner L, Beug H, Moriggl R, Sexl V (2009) The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) 14:2944–2958

Eckhoff K, Flurschutz R, Trillsch F, Mahner S, Janicke F, Milde-Langosch K (2013) The prognostic significance of Jun transcription factors in ovarian cancer. J Cancer Res Clin Oncol 139:1673–1680PubMed

Egloff AM, Grandis JR (2012) Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res 18:5188–5195PubMedCentralPubMed

Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11:1217–1228PubMed

Ellis RE, Yuan JY, Horvitz HR (1991) Mechanisms and functions of cell death. Annu Rev Cell Biol 7:663–698PubMed

Fan Y, Yu W, Ye P, Wang H, Wang Z, Meng Q, Duan Y, Liang X, An W (2011) NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol 30:241–245PubMed

Fishleder AJ (1990) Oncogenes and cancer: clinical applications. Cleve Clin J Med 57:721–726PubMed

Fister S, Gunthert AR, Aicher B, Paulini KW, Emons G, Grundker C (2009) GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res 69:6473–6481PubMed

Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK (2003) p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63:7081–7088PubMed

Fraser M, Bai T, Tsang BK (2008) Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122:534–546PubMed

George JA, Chen T, Taylor CC (2005) SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 65:10381–10388PubMed

Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627PubMed

Guan H, Zhang H, Cai J, Wu J, Yuan J, Li J, Huang Z, Li M (2011) IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-kappaB. J Pathol 223:436–445PubMed

Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ (2009) Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol 175:324–333PubMedCentralPubMed

Gupta N, Xu Z, El-Sehemy A, Steed H, Fu Y (2013) Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol Oncol 130:200–206PubMed

Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N (2011a) Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumour Biol 32:1031–1047PubMed

Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, Tanaka S, Sakuragi N (2011b) Clusterin is a potential molecular predictor for ovarian cancer patient’s survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res 30:113PubMedCentralPubMed

Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y (2000) Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60:5988–5994PubMed

Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178–2184PubMed

Hummel R, Wang T, Watson DI, Michael MZ, Van der Hoek M, Haier J, Hussey DJ (2011) Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep 26:1011–1017PubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMed

Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q (2013) Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. Cancer Lett 341:231–239PubMed

Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X, Lu B, Wu C, Ju J (2011) Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS ONE 6:e23271PubMedCentralPubMed

Johnson SW, Ozols RF, Hamilton TC (1993) Mechanisms of drug resistance in ovarian cancer. Cancer 71:644–649PubMed

Kato H, Arakawa A, Suzumori K, Kataoka N, Young SR (2004) FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples. Exp Mol Pathol 76:138–142PubMed

Kaur M, Radovanovic A, Essack M, Schaefer U, Maqungo M, Kibler T, Schmeier S, Christoffels A, Narasimhan K, Choolani M, Bajic VB (2009) Database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res 37:D820–D823PubMedCentralPubMed

Kloosterman WP, Plasterk RH (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11:441–450PubMed

Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, Timorek A, Dansonka-Mieszkowska A, Kupryjanczyk J (2009) PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 8:21–26PubMed

Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS (2011) MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 4:17PubMedCentralPubMed

Lee S, Choi EJ, Jin C, Kim DH (2005) Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97:26–34PubMed

Leong CT, Ong CK, Tay SK, Huynh H (2007) Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro. Oncogene 26:870–880PubMed

Leung TH, Wong SC, Chan KK, Chan DW, Cheung AN, Ngan HY (2013) The interaction between C35 and DeltaNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer 109:965–975PubMedCentralPubMed

Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG, Tsang BK (2001) Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142:370–380PubMed

Li Z, Gu X, Fang Y, Xiang J, Chen Z (2012) microRNA expression profiles in human colorectal cancers with brain metastases. Oncol Lett 3:346–350PubMedCentralPubMed

Lum E, Vigliotti M, Banerjee N, Cutter N, Wrzeszczynski KO, Khan S, Kamalakaran S, Levine DA, Dimitrova N, Lucito R (2013) Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. Gynecol Oncol 130:369–376PubMed

Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F, Milde-Langosch K (2008) C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99:1269–1275PubMedCentralPubMed

Manandhar S, Choi BH, Jung KA, Ryoo IG, Song M, Kang SJ, Choi HG, Kim JA, Park PH, Kwak MK (2012) NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity. Free Radic Biol Med 52:1773–1785PubMed

Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX (2003) Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278:19245–19256PubMed

Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM (2011) BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 17:6356–6366PubMedCentralPubMed

Mitamura T, Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N (2013) Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2:e40PubMedCentralPubMed

Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299PubMed

Moorehead RA, Singh G (2000) Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 59:337–345PubMed

Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q (2008) GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 9(Suppl 1):S4PubMedCentralPubMed

Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J (2006) Non-coding MicroRNAs hsa-let-7 g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3:317–324PubMedCentralPubMed

Ohta T, Isobe M, Takahashi T, Saitoh-Sekiguchi M, Motoyama T, Kurachi H (2009) The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Anticancer Res 29:4639–4647PubMed

Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609–619PubMed

Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M, Lin J (2000) Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20:407–416PubMed

Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC, O’Dwyer PJ (2002a) Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 63:1699–1707PubMed

Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK (2002b) Gamma-synuclein promotes cancer cell survival and inhibits stress—and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 277:35050–35060PubMed

Pan WW, Zhou JJ, Liu XM, Xu Y, Guo LJ, Yu C, Shi QH, Fan HY (2013) Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance. J Biol Chem 288:13620–13630PubMedCentralPubMed

Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC (2003) Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 309:377–383PubMed

Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556–562PubMed

Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, Gomes D, Cameselle-Teijeiro J, Vidal A, Martins TC, Sobrinho-Simoes M, Soares P (2011) Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 30:1302–1317PubMed

Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B, Wan Y (2005) Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 27:1441–1448PubMed

Qu D, Qu H, Fu M, Zhao X, Liu R, Sui L, Zhan Q (2008) Increased expression of Nlp, a potential oncogene in ovarian cancer, and its implication in carcinogenesis. Gynecol Oncol 110:230–236PubMed

Raffo AJ, Kim AL, Fine RL (2000) Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis. Oncogene 19:6216–6228PubMed

Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki Y, Miyazaki K (2012) Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol 138:535–544PubMed

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB (2012) A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 31:4559–4566PubMedCentralPubMed

Rose SL (2009) Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer 19:564–566PubMed

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ (2013) Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 130:554–559PubMed

Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM, Tothill RW, Gorringe KL, Campbell IG (2012) MicroRNA genes and their target 3′-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS ONE 7:e35805PubMedCentralPubMed

Scanlon KJ, Ishida H, Kashani-Sabet M (1994) Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci USA 91:11123–11127PubMedCentralPubMed

Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JH, Klijn JG, Look MP, Foekens JA, Stoter G, Berns EM (2001) Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85:1359–1367PubMedCentralPubMed

Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS (2008) Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 108:493–499PubMedCentralPubMed

Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO, Ratovitski E, Sidransky D (2011) DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res 71:1167–1176PubMedCentralPubMed

Sheng WJ, Jiang H, Wu DL, Zheng JH (2013) Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer. Braz J Med Biol Res 46:650–658PubMedCentralPubMed

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29PubMed

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30PubMed

Skirnisdottir I, Sorbe B, Seidal T (2001) The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I–II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11:119–129PubMed

Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR (2002) ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res 22:1993–1999PubMed

Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C (2008) Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111:478–486PubMed

Srikantan S, Abdelmohsen K, Lee EK, Tominaga K, Subaran SS, Kuwano Y, Kulshrestha R, Panchakshari R, Kim HH, Yang X, Martindale JL, Marasa BS, Kim MM, Wersto RP, Indig FE, Chowdhury D, Gorospe M (2011) Translational control of TOP2A influences doxorubicin efficacy. Mol Cell Biol 31:3790–3801PubMedCentralPubMed

Steller H (1995) Mechanisms and genes of cellular suicide. Science 267:1445–1449PubMed

Strobel T, Tai YT, Korsmeyer S, Cannistra SA (1998) BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene 17:2419–2427PubMed

Tang MK, Zhou HY, Yam JW, Wong AS (2010) c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 12:128–138PubMedCentralPubMed

Theurillat JP, Metzler SC, Henzi N, Djouder N, Helbling M, Zimmermann AK, Jacob F, Soltermann A, Caduff R, Heinzelmann-Schwarz V, Moch H, Krek W (2011) URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 19:317–332PubMed

Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456–1462PubMed

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719–725PubMedCentralPubMed

Vogt U, Falkiewicz B, Bielawski K, Bosse U, Schlotter CM (2000) Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay. Acta Biochim Pol 47:157–164PubMed

Vosa U, Vooder T, Kolde R, Fischer K, Valk K, Tonisson N, Roosipuu R, Vilo J, Metspalu A, Annilo T (2011) Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer 50:812–822PubMed

Wang SC, Hung MC (2000) Transcriptional targeting of the HER-2/neu oncogene. Drugs Today (Barc) 36:835–843

Wang Y, Kristensen GB, Helland A, Nesland JM, Borresen-Dale AL, Holm R (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124:392–401PubMed

Wang J, Zhou JY, Wu GS (2007) ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67:11933–11941PubMed

Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ (2011) Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 56:365–375PubMed

Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe ES, Calvo KR (2012) MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 97:586–594PubMedCentralPubMed

Wei L, Xue T, Wang J, Chen B, Lei Y, Huang Y, Wang H, Xin X (2009) Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer 125:791–806PubMed

Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, Zhou J, Xu G, Meng L, Zhu T, Wang S, Ma D (2009) Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett 273:257–265PubMed

Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D (2008) Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 271:260–271PubMed

Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P (2013) Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 71:1159–1171PubMed

Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G, Gao X (2013) MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33:378–386PubMed

Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y, Ma D (2008) Activation of fibronectin/PI-3 K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 261:108–119PubMed

Xu FJ, Stack S, Boyer C, O’Briant K, Whitaker R, Mills GB, Yu YH, Bast RC Jr (1997) Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3:1629–1634PubMed

Yamamoto S, Tsuda H, Honda K, Onozato K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O (2009) Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol 22:499–507PubMed

Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285–291PubMed

Yang N, Huang J, Greshock J, Liang S, Barchetti A, Hasegawa K, Kim S, Giannakakis A, Li C, O’Brien-Jenkins A, Katsaros D, Butzow R, Coukos G, Zhang L (2008) Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS ONE 3:e1758PubMedCentralPubMed

Yang G, Xiao X, Rosen DG, Cheng X, Wu X, Chang B, Liu G, Xue F, Mercado-Uribe I, Chiao P, Du X, Liu J (2011) The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res 17:2181–2194PubMedCentralPubMed

Yin F, Liu X, Li D, Wang Q, Zhang W, Li L (2013) Tumor suppressor genes associated with drug resistance in ovarian cancer (review). Oncol Rep 30:3–10PubMed

Yu D (1998) The role of oncogenes in drug resistance. Cytotechnology 27:283–292PubMedCentralPubMed

Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ (2003) AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278:23432–23440PubMed

Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C, Wei Y (2011) BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and-resistant ovarian cancer cells. PLoS ONE 6:e20586PubMedCentralPubMed

Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB, Turkson J (2012) Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 31:2309–2322PubMedCentralPubMed

Zhang Y, Dang C, Ma Q, Shimahara Y (2005) Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol Rep 14:161–171PubMed

Zhang X, Liu P, Zhang B, Wang A, Yang M (2010) Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 197:46–53PubMed

Zhang P, Zhou M, Jiang H, Zhang H, Shi B, Pan X, Gao H, Sun H, Li Z (2013) Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer. Carcinogenesis 34:2639–2646PubMed

Zhao M, Sun J, Zhao Z (2012a) Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer. PLoS ONE 7:e44175PubMedCentralPubMed

Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F, Hu W, Yuan Z, Nie C, Wei Y (2012b) JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J 444:291–301PubMed

Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC (2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027–8031PubMed

Zhou T, Bao Y, Ye S, Weng D, Chen G, Lu Y, Ma D, Wang S (2010) Effect of spindle checkpoint on Akt2-mediated paclitaxel-resistance in A2780 ovarian cancer cells. J Huazhong Univ Sci Technol Med Sci 30:206–211PubMed

Zhu W, Shan X, Wang T, Shu Y, Liu P (2010) miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127:2520–2529PubMed

Titel: Oncogenes associated with drug resistance in ovarian cancer
verfasst von: Xia Liu
Yutao Gao
Yi Lu
Jian Zhang
Li Li
Fuqiang Yin
Publikationsdatum: 01.03.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1765-5

Springer Medizin

Oncogenes associated with drug resistance in ovarian cancer

Abstract

Purpose

Methods

Results

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Retraction Note to: Randomized clinical trial of arginine-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing gastric cancer surgery

Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients

Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!

Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer

Ezrin-expressing lung adenocarcinoma cells and podoplanin-positive fibroblasts form a malignant microenvironment

Down-regulation of BTG3 promotes cell proliferation, migration and invasion and predicts survival in gastric cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie